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Background: The incidence of oropharyngeal cancer is increasing in the developed world. This has led to a large
rise in research activity and clinical trials in this area, yet there is no consensus on which outcomes should be
measured. As a result, the outcomes measured often differ between trials of comparable interventions, making the
combination or comparison of results between trials impossible. Outcomes may also be ‘cherry-picked’, such that
favourable results are reported, and less favourable results withheld. The development of a minimum outcome
reporting standard, known as a core outcome set, goes some way to addressing these problems. Core outcome
sets are ideally developed using a patient-centred approach so that the outcomes measured are relevant to patients
and clinical practice. Core outcome sets drive up the quality and relevance of research by ensuring that the right
outcomes are consistently measured and reported in trials in specific areas of health or healthcare.
Methods/Design: This is a mixed methods study involving three phases to develop a core outcome set for
oropharyngeal cancer clinical trials. Firstly, a systematic review will establish which outcomes are measured in
published oropharyngeal cancer randomised controlled trials (RCTs). Secondly, qualitative interviews with patients
and carers in the UK and the USA will aim to establish which outcomes are important to these stakeholders. Data
from these first two stages will be used to develop a comprehensive list of outcomes to be considered for
inclusion in the core outcome set. In the third stage, patients and clinicians will participate in an iterative consensus
exercise known as a Delphi study to refine the contents of the core outcome set. This protocol lays out the
methodology to be implemented in the CONSENSUS study.
Discussion: A core outcome set defines a minimum outcome reporting standard for clinical trials in a particular
area of health or healthcare. Its consistent implementation in oropharyngeal cancer clinical trials will improve the
quality and relevance of research.
Trials and registration: This study is registered at the National Institute for Health Research (NIHR) Clinical
Research Network (CRN) portfolio, ID 13823 (17 January 2013).
Keywords: Core outcome set, Consensus, Delphi, Oropharyngeal cancer, Head and neck cancer* Correspondence: aoife.waters@liverpool.ac.uk
1Department of Biostatistics, University of Liverpool, 1st Floor Duncan
Building, Daulby Street, Liverpool L69 3GA, UK
2Department of Molecular and Clinical Cancer Medicine, Liverpool Cancer
Research UK Centre, University of Liverpool, 200 London Road, Liverpool L3
9TA, UK
Full list of author information is available at the end of the article
© 2014 Waters et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Waters et al. Trials 2014, 15:168 Page 2 of 9
http://www.trialsjournal.com/content/15/1/168Background
Around 1,500 cases of oropharyngeal squamous cell car-
cinoma (OPSCC) are diagnosed in the UK every year
[1]. Treatment relies on radiotherapy (RT), surgery with
or without post-operative RT or cisplatin-based chemo-
radiotherapy (CRT), CRT alone or following induction
chemotherapy. Increasingly, small molecule adjuvants
are also being used. Multi-modality therapy is associated,
to varying degrees, with long-term deficits in speech and
swallowing function, cosmesis and health-related quality
of life.
While the incidence of squamous cancers at most sub-
sites of the head and neck is decreasing, the incidence of
OPSCC has doubled in the last decade; and this trend is
seen throughout the developed world [2,3]. Oncogenic
human papillomavirus type 16 (HPV-16) has been estab-
lished as the causative agent and has given rise to a clini-
copathologically distinct form of OPSCC that occurs in
a younger patient population and is associated with im-
proved survival outcomes, compared with HPV-negative
disease [4,5].
Contemporary treatments for HPV-positive and HPV-
negative OPSCC are, however, still the same and treat-
ment survivors suffer from long-term sequelae of
multi-modality therapy, to varying degrees. Clinical
trials in HPV-positive disease are largely focused on
deintensifying treatment to improve functional out-
comes whilst maintaining the advantageous survival
outcomes; however, current research in HPV-negative
disease remains focused on improving survival out-
comes, with less apparent focus on reducing toxicity
and improving functional outcomes. This is largely
due to the fact that overall survival rates for HPV-
negative disease have remained stubbornly resistant
to improvement for many decades.
Despite the fact that available treatments have a sig-
nificant impact on functioning and quality of life, such
outcomes are inconsistently measured and reported be-
tween trials. Additionally, there is no standardisation of
outcome selection and reporting, even among trials of
comparable interventions. This reduces the amount of
data contributable for meta-analyses, leading to difficul-
ties in interpreting treatment effect and in making
evidence-based healthcare decisions. The development
of a minimum outcome reporting standard for OPSCC
clinical trials, known as a core outcome set, is one
method proposed to address these problems.
A core outcome set defines the outcomes that should
be consistently measured and reported in clinical trials
in a specific area of health or healthcare. They are devel-
oped using consensus methods involving major stake-
holders, such as patients and healthcare professionals, to
ensure that the outcomes included are clinically relevant
and therefore ‘core’.The existence of a core outcome set does not mean
that only these outcomes should be measured; however,
if a minimum outcome reporting standard is adhered to,
then there will be greater consistency of reporting in
clinical trials and a greater body of evidence to contrib-
ute to meta-analyses to inform healthcare decisions.
Additionally, the risk of outcome reporting bias is
lessened by ensuring that outcomes are consistently
measured and reported.
The earliest efforts to improve outcome measurement
in clinical trials were made by the Outcome Measures in
Rheumatology (OMERACT) collaboration in the early
1990s [6]. This international network developed core sets
of measures for most of the major rheumatological con-
ditions, and an observational review by Kirkham et al.
demonstrated an increase in the consistency of outcome
reporting across clinical trials in rheumatoid arthritis
(RA) in the years following publication of the RA core
outcome set [7].
The OMERACT collaboration has actively involved
patients in discussions about which outcomes to meas-
ure in trials since 2002 [8]. Patient involvement was
first proposed at the OMERACT meeting in 2000 when
participants considered what might be a ‘clinically
important change’ in response to treatment. It was
realised that the perspectives of patients are import-
ant in developing core outcome sets, and they have
been actively involved in, and significantly contributed
to, all subsequent OMERACT meetings. Patients have
enriched the OMERACT research agenda, provided in-
sights into patient participation in research and stimu-
lated patient involvement in health outcomes research
more broadly [9].
Other bodies are now recognising the importance of in-
volving patients in trial research. INVOLVE, the national
advisory group for the promotion and advancement of
public involvement in NHS, public health and social care
research, promotes the involvement of patients and the
public in discussions about clinical trials because ‘they are
the participants in trials and ultimately the people for
whom research is aimed to benefit’ [10]. The Core Out-
come Measures in Effectiveness Trials (COMET) Initiative
advocates the involvement of patients and the public in
decisions about which outcomes should be included in
core outcome sets in specific areas of health or healthcare.
The measurement of patient-reported outcomes
(PROs) in clinical trials has increased substantially in the
last 20 years [11]. These subjective measures help evalu-
ate the burden of disease and treatment from the
patient’s perspective. The CONSORT group have re-
cently published a PRO extension to their guidance that
aims to improve the reporting of PROs in trials to facili-
tate the use of results in informing clinical practice and
health policy [12].
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ber of clinical areas and their use is advocated, in the
UK, by the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) and the
Cochrane Collaboration [13,14]. Core outcome sets will
only influence the evidence base if they are actually im-
plemented, and as core outcome set developers we must
therefore actively engage with trialists, Cochrane Review
Groups, clinical guideline developers, research funders,
journal editors, regulators and trial registries to act as
advocates to ensure that their use is encouraged and
supported.
Study overview
The objective of the CONSENSUS (Squamous Cell
CarcinOma of the OropharyNx: Late PhaSE CliNical
TrialS; Core OUtcomeS) Study is to develop a core
outcome set for OPSCC clinical trials. This protocol pre-
sents the methodology to be used.
The first stage of the study will establish the current
standard of outcome reporting in clinical trials through
a systematic review of OPSCC randomised controlled
trials (RCTs). The second stage will involve qualitative
interviews with OPSCC patients and carers to establish
which outcomes are important to these key stakeholders.
The third part of the study will employ an iterative con-
sensus technique known as a Delphi study. We expect
that different stakeholder opinions about which out-
comes should be measured in clinical trials in OPSCC
will converge to achieve consensus on the outcomes in
the OPSCC core outcome set.
Methods/Design
CONSENSUS is a mixed methods study. The Delphi
questionnaire will be developed using a comprehensive
list of outcomes identified from a systematic review, and
outcomes identified from qualitative interviews with
OPSCC patients and their carers.
Ethical approval for this study was granted in the UK
by the Liverpool Central Research Ethics Committee
(reference 12/NW/0708). Approval at the University of
Texas MD Anderson Cancer Center (Houston, TX, USA)
was provided by the Institutional Review Board (protocol
number 2013-0285).
Systematic review
A systematic review will identify which outcomes are re-
ported in phase III RCTs of interventions for the treat-
ment of OPSCC. This review will be limited to English
language studies published in the last 10 years.
Search strategy
A broad-based search strategy will be used to identify all
published OPSCC and squamous cell carcinoma of thehead and neck (SCCHN) RCTs. This will be applied to
PubMed, Embase and the Cochrane Central Register of
Controlled Trials (CENTRAL) from 1 January 2003 to
14 May 2013 (Appendix A).
Types of studies and interventions
Any phase III RCT of a treatment for OPSCC with cura-
tive intent will be included. Only SCCHN trials that
comprise patients with OPSCC will be included.
Types of participants
Adults aged over 18 years with OPSCC.
Exclusion criteria
Studies without OPSCC patients, studies involving pa-
tients with recurrent or metastatic disease, and studies
of interventions for the treatment of the side-effects of
treatment, such as xerostomia.
Eligibility of studies
Two reviewers (AW and a second reviewer) will inde-
pendently assess the identified records. A large number
of records will be identified by our search strategy,
therefore studies will be excluded in three phases. All
identified study titles will be reviewed and ineligible
studies excluded. Studies that are eligible from the title
or for which there is uncertainty will have their abstracts
reviewed in the second phase. Again, studies that are eli-
gible or for which there is uncertainty will have their full
papers reviewed in the third phase.
In order to ensure accuracy of exclusion, a proportion
of all included/excluded titles, abstracts and full papers
will be reviewed by two senior authors (TMJ and CTS).
A proportion of the studies excluded by title will have
their abstracts reviewed. If more than 1% of these studies
are found to be eligible then a further proportion of the
same amount will be reviewed, until 1% or less of further
studies in the re-review sample are eligible.
Data extraction
Outcomes will be identified within the methods and re-
sults section of each paper, and for each outcome we will
assess how it was defined and measured, the number of
participants in which it was measured, whether it was
measured using a validated tool, and whether it was
stated in both the methods and results. The individual
outcomes will be categorised under broader outcome
domains.
Data analysis
All eligible studies will be tabulated, and the identified
outcomes presented along with their definitions and
method of measurement. We also wish to identify any
heterogeneity in the definitions of outcomes and the way
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suggested that outcomes with the same name are often
defined or measured in different ways. We therefore
wish to establish whether outcomes are defined and, if
they are, whether there is heterogeneity in these defi-
nitions between studies which would make comparison
of these outcomes between trials more difficult, if not
impossible.
The identified outcomes will be categorised under
broader outcome domains which will be decided upon
by the study team. For functional outcomes, this process
will be guided by the International Classification of
Functioning, Disability and Health (ICF) categories for
head and neck cancer [15].
Qualitative interviews
The objectives of the qualitative part of the study are to
establish which outcomes are valued by patients and
carers, and which outcomes they feel should be included
in a core outcome set. The journey from diagnosis
through treatment is often a turbulent one for patients
with OPSCC and qualitative methods will be particularly
useful in helping us to understand their experiences of
treatment. Spouses will also be interviewed as they al-
most universally become carers to their partners during
this time and can provide an expert witness account of
events whilst helping to contextualise the importance of
different outcomes.
Participants
Patients with OPSCC and their carers will be recruited
to participate in qualitative interviews, from two centres
in the UK and one in the USA. A carer is defined as a
family member or spouse who provides informal care to
the patient during their treatment and recovery. Patient
and carer participants will be recruited from SCCHN
survivorship clinics. Patient participants will be adults,
aged 18 to 100 years, who are English speaking and up
to 5 years post-treatment for OPSCC. Carers of eligible
patient participants will also be invited to interview.
Eligible patients will be recruited from the outpatient
clinic in a chronological order to avoid the risk that
clinic staff will ‘cherry-pick’ patients who they anticipate
will present a favourable account of their experiences.
We will monitor the clinical and socio-demographic
characteristics of our patient sample, and ensure max-
imum diversity in terms of the following characteristics:
age, gender, sub-site, stage, HPV status, treatment mo-
dality and length of time since treatment. Maximum di-
versity sampling, a type of purposive sampling, is widely
used in qualitative research with the aim of accessing a
range of perspectives on the topic under investigation
[16]. We will interview NHS patients in the UK, for
whom care is provided free at the point of delivery andpatients attending the University of Texas MD Anderson
Cancer Center, which is a fee-paying institution. The UK
and US groups will differ in their socio-economic cir-
cumstances, thus the sample encompasses diversity on
this characteristic, which is well-recognised as having a
significant impact on outcomes in SCCHN patients [17].
HPV status will not be available for patients whose
diagnosis and treatment preceded testing for HPV. How-
ever, we will endeavour to recruit a mix of HPV-positive
and HPV-negative patients.
We expect to recruit around 30 patients and carers
in total, although this may change depending on early
analyses.
Interview format
A semi-structured interview format will be used. Partici-
pants will be required to provide informed consent prior
to interview. Conversation will be guided by a prompt
guide of open-ended questions on topics such as diagno-
sis and treatment, and the effect the cancer and treat-
ment had on participants’ lives, both at the time of
treatment and at the time of the interviews. Therefore,
whilst the interview will be conversational in nature, dis-
cussion will be directed towards identifying outcomes of
importance to patients and carers. Towards the end of
the interviews we will directly ask participants which
outcomes they think are most important and should be
measured in clinical trials. Key to this interview tech-
nique is that it allows participants to explain their ex-
perience of the illness and treatment in their own terms,
and to raise and focus on the aspects of their journey
that are most important to them.
Interview analysis
In line with the principles of qualitative research, the
analytical process will begin during data collection, as
the data already gathered are analysed to inform the on-
going data collection. This will allow the study team to
go back and refine questions, develop hypotheses, and
pursue emerging avenues of inquiry in further depth in
subsequent interviews [18].
We will take an interpretive approach, informed by
the principles of the constant comparative method and
by several procedural steps to ensure the quality of the
analysis [19]. This involves an inductive process of iden-
tifying analytical categories as they emerge from the data
(developing hypotheses from the ground or research
field upwards rather defining them a priori). The ana-
lysis of patients’ and carers’ accounts will initially
proceed in parallel, but related, courses. We shall analyse
within each group for common themes, such as what is
important to patients/carers, and how their lives have
been affected by the cancer and treatment [20]. As the
analysis develops we will compare across the different
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will examine how participants present their accounts as
well as the content of the interviews. That is, we will not
simply take participants’ accounts at face value.
We will compare data across the different groups
(age, gender, sub-site, stage, HPV status, treatment
modality, socio-economic status and length of time
since treatment) and analyse for patterns in how these
characteristics shape participants’ priorities following
cancer treatment. As the principal investigator (PI),
AW will lead a process of ‘cycling’ between the devel-
oping analysis and new data, and the complete team
will develop and ‘test’ the analysis by periodic discus-
sion of transcripts and reports on the developing ana-
lysis. Initially, each transcript will be read several times
by AW before developing open codes to describe each
relevant unit of meaning. Initial open coding will occur
at multiple levels, from detailed descriptions of experi-
ences line by line, to the general stance participants
take towards different aspects of their lives. Through
comparison within and across the transcripts the open
codes will gradually be developed into theoretical cat-
egories and subcategories, to reflect and test the devel-
oping analysis.
The categories will be organised into a framework to
code and index the transcripts using NVivo qualitative
data analysis software (version 10, 2012; QSR International
Pty Ltd, Victoria, Australia). The framework categories will
be continually checked and modified to ensure an adequate
‘fit’ with the data, whilst also accounting for variant or ex-
ceptional cases. The categories and the assignment of data
to them will be reviewed by a second member of the pro-
ject team.The Delphi method
In order to gather opinion and to reduce the number of
outcomes to a priority list for consideration in future
OPSCC clinical trials we will use the Delphi method.
This was originally developed by the RAND Corporation
in the 1950s in order to forecast the influence of tech-
nology on warfare [21]. It is an iterative consensus tech-
nique which comprises sequential questionnaires answered
anonymously by a panel of participants with relevant
expertise [6].
Questioning takes place in rounds, and after each
round of questions, an anonymous summary of the re-
sponses is fed back to the group. Individual participants
may then decide to keep their original answers or to
change their opinion in the subsequent round of voting.
The advantage of this approach is that it is not face-to-
face, and therefore avoids the problem of more vocal or
apparently senior participants dominating the group dis-
cussion and therefore influencing others’ voting.In general, the range of answers decreases and the
group converges towards a consensus opinion over the
course of several rounds. The process terminates after a
pre-defined stop criterion, which for this study will be
whichever occurs first: reduction of the long list of out-
comes to ten or less; or on completion of the second
round of voting.
Synthesis of outcomes into Delphi questionnaire
Outcomes from systematic review
The outcomes highlighted in the systematic review will
be categorised under broader outcome domains, and
presented in the questionnaire as such.
Outcomes from interviews
Identifying measureable outcomes from the interview
transcripts will be a more complex process. While some
outcomes are likely to be obvious, the context must al-
ways be borne in mind, and it is important that our in-
terpretation of the interview transcripts avoids either
overlooking outcomes of importance to participants or
misrepresenting them. For example, how extensively a
participant talks about a particular aspect of their life is
not necessarily indicative of its importance to them,
since patients may talk about highly significant issues in
a seemingly brief and casual manner as a way of man-
aging their emotions. We will begin by analysing tran-
scripts to identify experiences and priorities that map
straightforwardly to obviously measurable outcomes. Ex-
amples include mouth dryness, difficulty swallowing and
fatigue. Secondly, where a participant has described an
experience or issue that was significant for them, the
study team will attempt to map this to a measurable out-
come. An example of this could be anxiety about sur-
vivorship clinic appointments, which is likely to be an
expression of a patient’s anxieties about recurrence and
survival. One researcher (AW) will be responsible for
making these interpretations, and two researchers (AW
and BY) will review a proportion of the outcomes and
the supporting evidence from the interview transcript to
scrutinise and ‘test’ the plausibility of the interpretations
involved in translating participants’ accounts of their ex-
periences and priorities into outcomes. Any uncertainties
and a proportion of all outcomes derived through this
process will be discussed with the whole study team
(AW, CTS, BY, TMJ).
Patient interviews will be given primacy over the carer
interviews in the analysis and derivation of outcomes.
The carer acts as a witness to the patient’s experience
and therefore their accounts will be used largely to illu-
minate our analysis of the patient accounts. For example,
we will identify how far carers confirm or refute patient
accounts; where divergences arise we will return to the
patient accounts to identify the reasons for these or
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view data will also be used to inform the presentation
and labelling of outcomes, particularly for patients, in
the Delphi study.
Participants
The Delphi study will survey individuals with a stake in
clinical trials for OPSCC. This includes OPSCC patients
and their carers, and healthcare professionals involved in
the management of patients with OPSCC, namely, med-
ical and surgical oncologists, speech and language thera-
pists (SLTs), and head and neck clinical nurse specialists
(CNSs). It is important that a proportion of our clinician
participants are also involved in research or clinical tri-
als; therefore, we will recruit medical and surgical oncol-
ogists and SLTs from a list of those involved in a
multicentre SCCHN trial that is ongoing and coordi-
nated by our unit, and CNSs through personal contacts
and professional bodies.
In the UK, patient and carer interviewees will be
approached about participation in the Delphi study at
the time of the interview. Additional patient and carer
participants will be identified within survivorship clinics.
The Delphi questionnaire will be included with a postal
invitation, and a follow-up telephone call will be made
7 days following postage to confirm that the question-
naire was received. Clinician participants will be invited
by email to participate in an online Delphi questionnaire
and a reminder email will be sent after 7 days. The invi-
tation will clearly state the importance of completing all
rounds of the Delphi study. Attrition is more likely in par-
ticipants with minority opinions and this can lead to an
overestimation of the degree of consensus in the final re-
sults [6]. It will be clearly stated that outcomes important
to that individual may not be included in the final core out-
come set.
Definition of consensus
This must be defined upfront to avoid consensus being
defined in a way that could bias the results towards the
beliefs of the research team. For an outcome to be in-
cluded in the core outcome set there must be majority
agreement of the critical importance of an outcome,
and minority agreement that the outcome is not im-
portant. Conversely, for an outcome to be excluded
there must be majority agreement that the outcome is
not important, and only minority agreement that it is
critically important. These judgements are based on
GRADE Working Group recommendations and are dis-
cussed in further detail below [22,23].
Statistical considerations
There are no recommendations for the number of par-
ticipants to include in a Delphi study. In a systematicreview by Sinha et al. of studies using the Delphi
method in core outcome set development, the number
of participants ranged from 13 to 222 [6]. We have a
heterogeneous group of participants and therefore our
sample size will need to be slightly larger to account for
the likely diversity of opinions [24]. We aim to recruit
around 30 patients and carers, and 30 clinicians, who
will be medical and surgical oncologists, SLTs, and head
and neck CNSs.
Voting
In other Delphi studies a ‘blank sheet’ round has been
used to canvas participant opinion and generate a com-
prehensive and inclusive list of candidate outcomes. How-
ever, in conducting the systematic review and interviews
we have effectively completed this process.
Round 1
In round 1 of this Delphi study we will ask participants
to rate each of the outcomes using the GRADE process,
which suggests a 9-point scale (1 to 9) to rank their im-
portance [23]. There will also be room for participants
to add additional outcomes and to comment on why
they have ranked outcomes as they have. Rankings of 7
to 9 indicate outcomes of critical importance, ratings of
4 to 6 represent outcomes that are important but not
critical, while ratings of 1 to 3 are items that are deemed
to be of limited importance. All outcomes will be carried
through to the second round with first round scores dis-
played for each outcome. Consensus to carry an out-
come through to the core outcome set will be defined as
more than 70% of participants scoring its importance as
7 to 9 and less than 15% scoring it as 1 to 3. Additional
outcomes will be coded by the study team using the
same methods as for the interview and systematic re-
view. Feedback will be analysed using software adapted
from another Delphi study.
Round 2
The number and percentage of participants that allo-
cated each score will be presented to participants. How-
ever, feedback to each group will be randomised such
that some participants receive only their group’s voting
and others receive both groups’ voting. Participants
will then be asked to rate the outcomes again, using the
9-point scale.
Analysis of voting
The opinions of different groups can be analysed either
together or separately. Differences in opinion can be
accounted for by having separate panels for different
stakeholder groups [25]. It is not clear at this stage
whether patients and carers will have different opinions
to healthcare professionals. Macefield et al., in using a
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strated that the way in which feedback is delivered to
participants affects the voting in subsequent rounds
[26]. Feedback was randomised such that a proportion
of both stakeholder groups received feedback from both
stakeholder groups, and not just their own group. This
altered voting, especially by the clinician group. We will
randomise feedback such that half of the patient/carer
group will receive results from the patients’/carers’ first
round of voting, and half will receive results from pa-
tients/carers and clinicians. Similarly, half of the clini-
cians will receive results of the clinicians’ voting in the
first round, and half will receive feedback from both pa-
tients/carers and clinicians. It is important to ensure that
we have similar numbers between the panels for every
round so that the final consensus is not numerically
dominated by one group’s responses. As recommended
by Sinha et al., we will report a measure of the distribu-
tion of scores for each outcome considered in the final
round [6]. This is because cut-off scores, used in most
studies, do not describe how strongly the minority feel,
and so an apparent consensus could actually be masking
major disagreement within the group [27].
Consensus meeting
After round 2, the remaining outcomes will be reviewed.
If consensus has not been reached or there is significant
disagreement between the groups, we will conduct a face-
to-face meeting of 15 Delphi participants who are key
stakeholders (patients, carers, medical and surgical oncol-
ogists, SLTs, and CNSs) to resolve any disagreement, and
discuss the remaining outcomes and their application
within clinical trials. By the end of this process we should
have identified ‘what’ outcomes to measure, although we
may well not be clear on the best way of measuring these.
Discussion
A core outcome set for OPSCC will improve the con-
duct, reporting and contribution of clinical trials to the
existing body of evidence for OPSCC in the published
literature. We believe that establishing which outcomes
to measure takes priority over establishing how to meas-
ure these outcomes as any recommendation regarding a
specific instrument may well become outdated.
As stated previously, a core outcome set will only have
impact if it is consistently implemented in trials. We
must actively engage with trialists, regulators, and those
that fund and publish trials to ensure that our core out-
come set is used, and that there are incentives to use it,
not just in the UK but in the rest of the academic world.
Trial status
We are preparing to recruit participants to the Delphi
study.Appendix A
Search strategies for systematic review
PubMed search strategy: 1 January 2003 to 14 May 2013
1. “Oropharyngeal Neoplasms”[Mesh]
2. (“Head and Neck Neoplasms”[Mesh:NoExp])
3. “Otorhinolaryngologic Neoplasms”[Mesh:NoExp]
4. “Pharyngeal Neoplasms”[Mesh:NoExp]
5. “Neoplasms”[Mesh]
6. (cancer* OR carcinoma* OR neoplas* OR tumor*
OR tumour* OR malignan* OR SCC)
9. (#5 OR #6)
10. “Oropharynx”[Mesh]
11. (oropharyn* OR mesopharyn* OR tonsil* OR “head
and neck” OR “head neck” OR “head-neck” OR
“head-and-neck” OR “tongue base” OR “soft palate”)
12. (#10 OR #11)
13. (#9 AND #12)
14. (HNSCC ORSCCHN OR OP-SCC OR OPSCC)
15. (#1 OR #2 OR #3 OR #4 OR #13 OR #14)
16. ((((Randomized Controlled Trial[ptyp])) OR ((Con-
trolled Clinical Trial[ptyp])) OR ((Clinical Trial
[ptyp])) OR (“Clinical Trials as Topic”[Mesh])
OR (“Clinical Trials, Phase III as Topic”[Mesh]) OR
(“Clinical Trials, Phase IV as Topic”[Mesh]) OR
(“Controlled Clinical Trials as Topic”[Mesh])
OR (“Clinical Trial”[Publication Type]) OR (“Con-
trolled Clinical Trial”[Publication Type]) OR (“Clin-
ical Trial, Phase III”[Publication Type]) OR (“Clinical
Trial, Phase IV”[Publication Type]) OR (“Multi-
center Study”[Publication Type]) OR (“Multicenter
Studies as Topic”[Mesh]) OR (“Random Alloca-
tion”[Mesh]) OR (“Double-Blind Method”[Mesh])
OR (“Single-Blind Method”[Mesh]) OR (“Cross-
Over Studies”[Mesh]) OR (“Placebos”[Mesh]) OR
(controlled[tiab] AND (trial[tiab] OR trials[tiab]
OR study[tiab] OR studies[tiab])) OR (blind[tiab]
OR blinding[tiab] OR blinded[tiab] OR mask[tiab]
OR masking[tiab] OR masked[tiab] OR placebo
[tiab] OR placebos[tiab] OR rct[tiab] OR random
[tiab] OR randomised[tiab] OR randomized[tiab]
OR randomly[tiab] OR randomisation[tiab] OR
randomization[tiab]) OR (factorial[tiab]) OR (divided
[tiab] AND (group[tiab] OR groups[tiab])) OR
(crossover[tiab]) OR (“cross over”[tiab]) OR (multi-
centre[tiab] OR multicentred[tiab] OR multicentric
[tiab]) OR (versus[ti] OR vs[ti]) OR (“treatment
arm”[tiab]) OR (“phase III”[tiab] OR “phase three”
[tiab] OR “phase 3”[tiab]) OR (“latin square”[tiab])
NOT ((“Animals”[Mesh] OR mouse[ti] OR mice[ti]
OR pig[ti] OR pigs[ti] OR rat[ti] OR rats[ti] OR
rabbit*[ti]) NOT ((“Animals”[Mesh] OR mouse[ti]
OR mice[ti] OR pig[ti] OR pigs[ti] OR rat[ti] OR rats
[ti] OR rabbit*[ti] OR cadaver[ti] OR cadavers[ti])
AND (“Humans”[Mesh])))))
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18. ““Cochrane Database Syst Rev”“[Journal]
19. (“systematic review” OR “meta analysis”)
20. (#19 OR #18)
21. (#17 NOT #20)
Cochrane Central Register of Controlled Trials
(CENTRAL): 1 January 2003 to 14 May 2013
1. MeSH descriptor: [Oropharyngeal Neoplasms] ex-
plode all trees
2. MeSH descriptor: [Head and Neck Neoplasms] this
term only
3. MeSH descriptor: [Pharyngeal Neoplasms] this term
only
4. MeSH descriptor: [Otorhinolaryngologic Neoplasms]
this term only
5. MeSH descriptor: [Neoplasms] explode all trees
6. cancer* OR carcinoma* OR neoplas* OR tumor* OR
tumour* OR malignan* OR SCC
7. #5 OR #6
8. MeSH descriptor: [Oropharynx] explode all trees
9. oropharyn* OR mesopharyn* OR tonsil* OR “head
and neck” OR “head neck” OR “head-neck” OR
“head-and-neck” OR pharyn* OR “tongue base” OR
“soft palate”
10. #8 OR #9
11. #7 AND #10
12. HNSCC OR SCCHN OR OP-SCC OR OPSCC
13. #1 OR #2 OR #3 OR #4 OR #11 OR #12
Embase: 1 January 2003 to 14 May 2013
1. Exp Oropharynx tumor/
2. Pharynx cancer/
3. Neoplasm/
4. (cancer* OR carcinoma* OR neoplas* OR tumor*
OR tumour* OR malignan* OR SCC).tw.
5. #3 OR #4
6. exp OROPHARYNX/OR exp OROPHARYNX
CANCER/OR exp OROPHARYNX CARCINOMA/
7. (oropharyn* OR mesopharyn* OR tonsil* OR “head
and neck” OR “head neck” OR “head-neck” OR“head-
and-neck” OR pharyn* OR “tongue base” OR “soft
palate”).tw.
8. #6 OR #7
9. #5 AND #8
10. (HNSCC OR SCCHN OR OP-SCC OR OPSCC).tw.
11. #1 OR #2 OR #9 OR #10
12. (random* OR factorial* OR placebo* OR assign*
OR allocat*).mp. OR crossover*.tw. [mp = title, ab-
stract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
13. (cross adj over*).tw.
14. (cross adj over*).tw.
15. ((blind* OR mask*) and (single OR double OR
triple OR treble)).tw.16. (treatment adj arm*).tw.
17. (control* adj group*).tw.
18. (phase adj III).mp. OR three.tw. [mp = title, ab-
stract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
19. (versus OR vs).tw.
20. rct.tw.
21. CROSSOVER PROCEDURE/
22. DOUBLE BLIND PROCEDURE/
23. SINGLE BLIND PROCEDURE/
24. RANDOMIZATION/
25. PLACEBO/
26. exp CLINICAL TRIAL/
27. PARALLEL DESIGN/
28. LATIN SQUARE DESIGN/
29. #12 OR #13 OR #14 OR #15 OR #16 OR #17
OR #18 OR #19 OR #20 OR #21 OR #22 OR
#23 OR #24 OR #25 OR #26 OR #27 OR #28
30. #11 AND #29
31. limit #30 to human
32. “systematic review”.tw.
33. #31 NOT #32
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